id,star_annotation,gene_id,drug_id,allele,phenotype,reference_id,P-value,source,id_in_source,region,Country_of_Participants
STAR1,CYP1A2*1K,PHARGENE19,DRUG10,*1K,CYP1A2 *1K is associated with decreased metabolism of caffeine in healthy individuals.,REF162,< 0.02,PharmGKB,827698390,Sub-Saharan African,Ethiopia
STAR2,CYP3A4*1,PHARGENE27,DRUG12,*1/*22 + *22/*22,CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.,REF152,0.01,PharmGKB,1184746928,African American/Afro-Caribbean,USA
STAR3,CYP3A4*22,PHARGENE27,DRUG12,*1/*22 + *22/*22,CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.,REF152,0.01,PharmGKB,1184746928,African American/Afro-Caribbean,USA
STAR196,CYP3A4*1,PHARGENE27,DRUG55,*1/*1B,CYP3A4 *1/*1B is associated with increased dose of buprenorphine in people with Opioid-Related Disorders.,REF160,,PharmGKB,1449170970,African American/Afro-Caribbean,USA
STAR197,CYP3A4*1B,PHARGENE27,DRUG55,*1/*1B,CYP3A4 *1/*1B is associated with increased dose of buprenorphine in people with Opioid-Related Disorders.,REF160,,PharmGKB,1449170970,African American/Afro-Caribbean,USA
STAR218,CYP3A4*1,PHARGENE27,DRUG11,*1/*1B,CYP3A4 *1/*1B is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.,REF54,< 0.005,PharmGKB,1447674678,North African,Tunisia
STAR219,CYP3A4*1B,PHARGENE27,DRUG11,*1/*1B,CYP3A4 *1/*1B is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.,REF54,< 0.005,PharmGKB,1447674678,North African,Tunisia
STAR220,CYP3A5*1A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A,CYP3A5 *1A/*1A + *1A/*3A is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A.,REF54,< 0.005,PharmGKB,1447674691,North African,Tunisia
STAR221,CYP3A5*3A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A,CYP3A5 *1A/*1A + *1A/*3A is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A.,REF54,< 0.005,PharmGKB,1447674691,North African,Tunisia
STAR175,CYP3A5*3A,PHARGENE28,DRUG11,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.,REF39,,PharmGKB,1448267244,African American/Afro-Caribbean,USA
STAR176,CYP3A5*6,PHARGENE28,DRUG11,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.,REF39,,PharmGKB,1448267244,African American/Afro-Caribbean,USA
STAR177,CYP3A5*7,PHARGENE28,DRUG11,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased clearance of tacrolimus in people with Kidney Transplantation.,REF39,,PharmGKB,1448267244,African American/Afro-Caribbean,USA
STAR193,CYP3A5*1A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,0.04,PharmGKB,1449170428,African American/Afro-Caribbean,USA
STAR194,CYP3A5*3A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,0.04,PharmGKB,1449170428,African American/Afro-Caribbean,USA
STAR195,CYP3A5*6,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,0.04,PharmGKB,1449170428,African American/Afro-Caribbean,USA
STAR206,CYP3A5*1A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,< 0.01,PharmGKB,1449171185,African American/Afro-Caribbean,USA
STAR207,CYP3A5*3A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,< 0.01,PharmGKB,1449171185,African American/Afro-Caribbean,USA
STAR208,CYP3A5*6,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *6/*6.,REF109,< 0.01,PharmGKB,1449171185,African American/Afro-Caribbean,USA
STAR198,CYP3A5*1A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6 + *1A/*7,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 + *1A/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *3A/*7 + *6/*6 + *6/*7 + *7/*7.,REF164,< 0.001,PharmGKB,1449183103,African American/Afro-Caribbean,USA
STAR199,CYP3A5*3A,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6 + *1A/*7,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 + *1A/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *3A/*7 + *6/*6 + *6/*7 + *7/*7.,REF164,< 0.001,PharmGKB,1449183103,African American/Afro-Caribbean,USA
STAR200,CYP3A5*6,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6 + *1A/*7,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 + *1A/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *3A/*7 + *6/*6 + *6/*7 + *7/*7.,REF164,< 0.001,PharmGKB,1449183103,African American/Afro-Caribbean,USA
STAR201,CYP3A5*7,PHARGENE28,DRUG11,*1A/*1A + *1A/*3A + *1A/*6 + *1A/*7,CYP3A5 *1A/*1A + *1A/*3A + *1A/*6 + *1A/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3A/*3A + *3A/*6 + *3A/*7 + *6/*6 + *6/*7 + *7/*7.,REF164,< 0.001,PharmGKB,1449183103,African American/Afro-Caribbean,USA
STAR4,CYP2A6*1A,PHARGENE20,DRUG18,*1A/*20,CYP2A6 *1A/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.,REF129,,PharmGKB,827827639,African American/Afro-Caribbean,USA & Japan
STAR5,CYP2A6*20,PHARGENE20,DRUG18,*1A/*20,CYP2A6 *1A/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.,REF129,,PharmGKB,827827639,African American/Afro-Caribbean,USA & Japan
STAR12,CYP2A6*17,PHARGENE20,DRUG18,*17/*20,CYP2A6 *17/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.,REF129,,PharmGKB,827827648,African American/Afro-Caribbean,USA & Japan
STAR13,CYP2A6*1A,PHARGENE20,DRUG18,*17/*20,CYP2A6 *17/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.,REF129,,PharmGKB,827827648,African American/Afro-Caribbean,USA & Japan
STAR14,CYP2A6*20,PHARGENE20,DRUG18,*17/*20,CYP2A6 *17/*20 is associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1A/*1A.,REF129,,PharmGKB,827827648,African American/Afro-Caribbean,USA & Japan
STAR6,CYP2A6*1A,PHARGENE20,DRUG18,*1X2B,CYP2A6 *1X2B is associated with increased metabolism of nicotine as compared to CYP2A6 *1A.,REF58,,PharmGKB,827827796,African American/Afro-Caribbean,USA & Japan
STAR7,CYP2A6*1X2B,PHARGENE20,DRUG18,*1X2B,CYP2A6 *1X2B is associated with increased metabolism of nicotine as compared to CYP2A6 *1A.,REF58,,PharmGKB,827827796,African American/Afro-Caribbean,USA & Japan
STAR8,CYP2A6*17,PHARGENE20,DRUG18,*4A/*17 + *9/*26,CYP2A6 *4A/*17 + *9/*26 are associated with decreased metabolism of nicotine.,REF17,,PharmGKB,1447982613,African American/Afro-Caribbean,USA
STAR9,CYP2A6*26,PHARGENE20,DRUG18,*4A/*17 + *9/*26,CYP2A6 *4A/*17 + *9/*26 are associated with decreased metabolism of nicotine.,REF17,,PharmGKB,1447982613,African American/Afro-Caribbean,USA
STAR10,CYP2A6*4A,PHARGENE20,DRUG18,*4A/*17 + *9/*26,CYP2A6 *4A/*17 + *9/*26 are associated with decreased metabolism of nicotine.,REF17,,PharmGKB,1447982613,African American/Afro-Caribbean,USA
STAR11,CYP2A6*9,PHARGENE20,DRUG18,*4A/*17 + *9/*26,CYP2A6 *4A/*17 + *9/*26 are associated with decreased metabolism of nicotine.,REF17,,PharmGKB,1447982613,African American/Afro-Caribbean,USA
STAR209,CYP2A6*2,PHARGENE20,DRUG5,*2,CYP2A6 *2 is associated with decreased metabolism of efavirenz in people with HIV.,REF20,< 0.05,PharmGKB,827803602,Mixed Population containing african descendant groups,
STAR63,CYP2B6*6,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with metabolism of efavirenz in people with HIV.,REF81,2.34e-07,PharmGKB,1183944291,Sub-Saharan African,Uganda
STAR64,CYP2B6*1,PHARGENE21,DRUG5,*1/*1,CYP2B6 *1/*1 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.,REF81,ambiguous,PharmGKB,1183764170,Sub-Saharan African,Uganda
STAR65,CYP2B6*6,PHARGENE21,DRUG5,*1/*1,CYP2B6 *1/*1 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.,REF81,ambiguous,PharmGKB,1183764170,Sub-Saharan African,Uganda
STAR66,CYP2B6*1,PHARGENE21,DRUG5,*1/*6,CYP2B6 *1/*6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.,REF81,,PharmGKB,1183771932,Sub-Saharan African,Uganda
STAR67,CYP2B6*6,PHARGENE21,DRUG5,*1/*6,CYP2B6 *1/*6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 *6/*6.,REF81,,PharmGKB,1183771932,Sub-Saharan African,Uganda
STAR111,CYP2B6*6,PHARGENE21,DRUG5,*6/*6,CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV.,REF159,0.016,PharmGKB,1184988338,Sub-Saharan African,Zimbabwe & Uganda
STAR112,CYP2B6*1,PHARGENE21,DRUG5,*1/*18,CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV.,REF159,0.016,PharmGKB,1184988346,Sub-Saharan African,Zimbabwe & Uganda
STAR113,CYP2B6*18,PHARGENE21,DRUG5,*1/*18,CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV.,REF159,0.016,PharmGKB,1184988346,Sub-Saharan African,Zimbabwe & Uganda
STAR114,CYP2B6*1,PHARGENE21,DRUG5,*1/*9,CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV.,REF159,0.016,PharmGKB,1184988354,Sub-Saharan African,Zimbabwe & Uganda
STAR115,CYP2B6*9,PHARGENE21,DRUG5,*1/*9,CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV.,REF159,0.016,PharmGKB,1184988354,Sub-Saharan African,Zimbabwe & Uganda
STAR179,CYP2B6*1,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.,REF110,,PharmGKB,1448997246,Sub-Saharan African,Uganda
STAR180,CYP2B6*6,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.,REF110,,PharmGKB,1448997246,Sub-Saharan African,Uganda
STAR181,CYP2B6*1,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.,REF26,,PharmGKB,1448995871,Sub-Saharan African,Uganda
STAR182,CYP2B6*6,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.,REF26,,PharmGKB,1448995871,Sub-Saharan African,Uganda
STAR189,CYP2B6*1,PHARGENE21,DRUG5,*11,CYP2B6 *11 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.,REF26,,PharmGKB,1448995884,Sub-Saharan African,Uganda
STAR190,CYP2B6*11,PHARGENE21,DRUG5,*11,CYP2B6 *11 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.,REF26,,PharmGKB,1448995884,Sub-Saharan African,Uganda
STAR191,CYP2B6*1,PHARGENE21,DRUG5,*6/*6,CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.,REF77,0.05,PharmGKB,1448995859,Sub-Saharan African,Tanzania
STAR192,CYP2B6*6,PHARGENE21,DRUG5,*6/*6,CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.,REF77,0.05,PharmGKB,1448995859,Sub-Saharan African,Tanzania
STAR204,CYP2B6*1,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 *1.,REF3,,PharmGKB,1447984366,Sub-Saharan African,Uganda
STAR205,CYP2B6*6,PHARGENE21,DRUG5,*6,CYP2B6 *6 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 *1.,REF3,,PharmGKB,1447984366,Sub-Saharan African,Uganda
STAR15,CYP2B6*1,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR16,CYP2B6*18,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR17,CYP2B6*22,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR18,CYP2B6*4,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR19,CYP2B6*5,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR20,CYP2B6*6,PHARGENE21,DRUG22,*1/*6 + *1/*18,CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,0.027,PharmGKB,1445403153,African American/Afro-Caribbean,USA
STAR146,CYP2B6*1,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR147,CYP2B6*18,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR148,CYP2B6*22,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR149,CYP2B6*4,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR150,CYP2B6*5,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR151,CYP2B6*6,PHARGENE21,DRUG22,*6/*6 + *6/*18,CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.,REF22,ambiguous,PharmGKB,1445403174,African American/Afro-Caribbean,USA
STAR118,CYP2C19*1,PHARGENE23,DRUG22,*2 + *17,CYP2C19 *2 + *17 are not associated with response to bupropion in people with Tobacco Use Disorder as compared to CYP2C19 *1.,REF124,> 0.05,PharmGKB,1184985821,African American/Afro-Caribbean,USA
STAR119,CYP2C19*17,PHARGENE23,DRUG22,*2 + *17,CYP2C19 *2 + *17 are not associated with response to bupropion in people with Tobacco Use Disorder as compared to CYP2C19 *1.,REF124,> 0.05,PharmGKB,1184985821,African American/Afro-Caribbean,USA
STAR120,CYP2C19*2,PHARGENE23,DRUG22,*2 + *17,CYP2C19 *2 + *17 are not associated with response to bupropion in people with Tobacco Use Disorder as compared to CYP2C19 *1.,REF124,> 0.05,PharmGKB,1184985821,African American/Afro-Caribbean,USA
STAR21,CYP3A5*1A,PHARGENE28,DRUG21,*3A/*3A,CYP3A5 *3A/*3A is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1A/*1A + *1A/*3A.,REF117,0.037,PharmGKB,981501747,African American/Afro-Caribbean,USA
STAR22,CYP3A5*3A,PHARGENE28,DRUG21,*3A/*3A,CYP3A5 *3A/*3A is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1A/*1A + *1A/*3A.,REF117,0.037,PharmGKB,981501747,African American/Afro-Caribbean,USA
STAR34,CYP3A5*3A,PHARGENE28,DRUG29,*3A/*3A,CYP3A5 *3A/*3A is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1A/*1A + *1A/*3A.,REF103,0.822,PharmGKB,982044254,Sub-Saharan African,Brazil
STAR121,CYP3A5*1A,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998561,African American/Afro-Caribbean,USA
STAR122,CYP3A5*3A,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998561,African American/Afro-Caribbean,USA
STAR123,CYP3A5*6,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998561,African American/Afro-Caribbean,USA
STAR124,CYP3A5*7,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998561,African American/Afro-Caribbean,USA
STAR125,CYP3A5*1A,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998461,African American/Afro-Caribbean,USA
STAR126,CYP3A5*3A,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998461,African American/Afro-Caribbean,USA
STAR127,CYP3A5*6,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998461,African American/Afro-Caribbean,USA
STAR128,CYP3A5*7,PHARGENE28,DRUG39,*3A + *6 + *7,CYP3A5 *3A + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1A.,REF57,ambiguous,PharmGKB,1184998461,African American/Afro-Caribbean,USA
STAR23,CYP2C9*9,PHARGENE25,DRUG27,*9,CYP2C9 *9 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.,REF155,,PharmGKB,981940156,Sub-Saharan African,Benin
STAR24,CYP2C9*11,PHARGENE25,DRUG27,*11,CYP2C9 *11 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.,REF155,,PharmGKB,981940175,Sub-Saharan African,Benin
STAR25,CYP2C9*8,PHARGENE25,DRUG27,*8,CYP2C9 *8 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.,REF155,,PharmGKB,981940163,Sub-Saharan African,Benin
STAR26,CYP2C9*5,PHARGENE25,DRUG27,*5,CYP2C9 *5 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.,REF155,,PharmGKB,981940181,Sub-Saharan African,Benin
STAR27,CYP2C9*6,PHARGENE25,DRUG27,*6,CYP2C9 *6 is not associated with increased response to acenocoumarol as compared to CYP2C9 *1.,REF155,,PharmGKB,981940169,Sub-Saharan African,Benin
STAR141,CYP2C9*1,PHARGENE25,DRUG27,*9/*11 + *5/*8,CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.,REF155,,PharmGKB,1444706610,Sub-Saharan African,Benin
STAR142,CYP2C9*11,PHARGENE25,DRUG27,*9/*11 + *5/*8,CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.,REF155,,PharmGKB,1444706610,Sub-Saharan African,Benin
STAR143,CYP2C9*5,PHARGENE25,DRUG27,*9/*11 + *5/*8,CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.,REF155,,PharmGKB,1444706610,Sub-Saharan African,Benin
STAR144,CYP2C9*8,PHARGENE25,DRUG27,*9/*11 + *5/*8,CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.,REF155,,PharmGKB,1444706610,Sub-Saharan African,Benin
STAR145,CYP2C9*9,PHARGENE25,DRUG27,*9/*11 + *5/*8,CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.,REF155,,PharmGKB,1444706610,Sub-Saharan African,Benin
STAR210,CYP2C9*1,PHARGENE25,DRUG27,*1/*2,CYP2C9 *1/*2 is not associated with dose of acenocoumarol.,REF35,0.904,PharmGKB,982010090,North African,Morocco
STAR211,CYP2C9*2,PHARGENE25,DRUG27,*1/*2,CYP2C9 *1/*2 is not associated with dose of acenocoumarol.,REF35,0.904,PharmGKB,982010090,North African,Morocco
STAR212,CYP2C9*1,PHARGENE25,DRUG27,*1/*1,CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.,REF35,0.0011,PharmGKB,982010010,North African,Morocco
STAR213,CYP2C9*1,PHARGENE25,DRUG27,*1/*1,CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.,REF35,0.0023,PharmGKB,982010082,North African,Morocco
STAR214,CYP2C9*1,PHARGENE25,DRUG27,*1/*3,CYP2C9 *1/*3 is not associated with dose of acenocoumarol.,REF35,0.904,PharmGKB,982010097,North African,Morocco
STAR215,CYP2C9*3,PHARGENE25,DRUG27,*1/*3,CYP2C9 *1/*3 is not associated with dose of acenocoumarol.,REF35,0.904,PharmGKB,982010097,North African,Morocco
STAR222,CYP2C9*1,PHARGENE25,DRUG27,*3,"CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.",REF13,< 0.0001,PharmGKB,1449188274,North African,Tunisia
STAR223,CYP2C9*3,PHARGENE25,DRUG27,*3,"CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.",REF13,< 0.0001,PharmGKB,1449188274,North African,Tunisia
STAR224,CYP2C9*1,PHARGENE25,DRUG27,*2,CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.,REF13,0.004,PharmGKB,1449188252,North African,Tunisia
STAR225,CYP2C9*2,PHARGENE25,DRUG27,*2,CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.,REF13,0.004,PharmGKB,1449188252,North African,Tunisia
STAR28,CYP2C9*1,PHARGENE25,DRUG28,*1/*8,CYP2C9 *1/*8 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134736215,Sub-Saharan African,Benin
STAR29,CYP2C9*8,PHARGENE25,DRUG28,*1/*8,CYP2C9 *1/*8 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134736215,Sub-Saharan African,Benin
STAR30,CYP2C9*1,PHARGENE25,DRUG28,*1/*6,CYP2C9 *1/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134049001,Sub-Saharan African,Benin
STAR31,CYP2C9*6,PHARGENE25,DRUG28,*1/*6,CYP2C9 *1/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134049001,Sub-Saharan African,Benin
STAR32,CYP2C9*1,PHARGENE25,DRUG28,*1/*11,CYP2C9 *1/*11 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134807206,Sub-Saharan African,Benin
STAR33,CYP2C9*11,PHARGENE25,DRUG28,*1/*11,CYP2C9 *1/*11 is not associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1134807206,Sub-Saharan African,Benin
STAR35,CYP2C9*1,PHARGENE25,DRUG28,*1/*5 + *5/*6,CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1133417241,Sub-Saharan African,Benin
STAR36,CYP2C9*5,PHARGENE25,DRUG28,*1/*5 + *5/*6,CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1133417241,Sub-Saharan African,Benin
STAR37,CYP2C9*6,PHARGENE25,DRUG28,*1/*5 + *5/*6,CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.,REF144,0.01,PharmGKB,1133417241,Sub-Saharan African,Benin
STAR40,CYP2C9*1,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF113,0.001,PharmGKB,1184510263,Sub-Saharan African,Sudan
STAR41,CYP2C9*11,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF113,0.001,PharmGKB,1184510263,Sub-Saharan African,Sudan
STAR42,CYP2C9*2,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF113,0.001,PharmGKB,1184510263,Sub-Saharan African,Sudan
STAR43,CYP2C9*5,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF113,0.001,PharmGKB,1184510263,Sub-Saharan African,Sudan
STAR44,CYP2C9*6,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF113,0.001,PharmGKB,1184510263,Sub-Saharan African,Sudan
STAR68,CYP2C9*1,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR69,CYP2C9*11,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR70,CYP2C9*2,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR71,CYP2C9*5,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR72,CYP2C9*6,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR73,CYP2C9*8,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR74,CYP2C9*9,PHARGENE25,DRUG1,*2 + *6 + *5 + *11,CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.,REF113,< 0.001,PharmGKB,1184510278,Sub-Saharan African,Sudan
STAR53,CYP2C9*1,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR54,CYP2C9*10,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR55,CYP2C9*11,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR56,CYP2C9*2,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR57,CYP2C9*3,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR58,CYP2C9*5,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR59,CYP2C9*6,PHARGENE25,DRUG1,*11 + *2 + *3 + *5 + *6,CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.,REF108,ambiguous,PharmGKB,1183701419,African American/Afro-Caribbean,USA
STAR60,CYP2C9*6,PHARGENE25,DRUG1,*6/*6,CYP2C9 *6/*6 is associated with decreased dose of warfarin.,REF4,,PharmGKB,1183701586,African American/Afro-Caribbean,USA
STAR61,CYP2C9*1,PHARGENE25,DRUG1,*8/*8,CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF60,,PharmGKB,1183700910,African American/Afro-Caribbean,USA
STAR62,CYP2C9*8,PHARGENE25,DRUG1,*8/*8,CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF60,,PharmGKB,1183700910,African American/Afro-Caribbean,USA
STAR131,CYP2C9*1,PHARGENE25,DRUG1,*5 + *6 + *11,CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296737,African American/Afro-Caribbean,USA
STAR132,CYP2C9*11,PHARGENE25,DRUG1,*5 + *6 + *11,CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296737,African American/Afro-Caribbean,USA
STAR133,CYP2C9*5,PHARGENE25,DRUG1,*5 + *6 + *11,CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296737,African American/Afro-Caribbean,USA
STAR134,CYP2C9*6,PHARGENE25,DRUG1,*5 + *6 + *11,CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296737,African American/Afro-Caribbean,USA
STAR137,CYP2C9*1,PHARGENE25,DRUG1,*1/*2 + *2/*2,CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296627,African American/Afro-Caribbean,USA
STAR138,CYP2C9*2,PHARGENE25,DRUG1,*1/*2 + *2/*2,CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296627,African American/Afro-Caribbean,USA
STAR139,CYP2C9*1,PHARGENE25,DRUG1,*1/*3 + *3/*3,CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296671,African American/Afro-Caribbean,USA
STAR140,CYP2C9*3,PHARGENE25,DRUG1,*1/*3 + *3/*3,CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF128,ambiguous,PharmGKB,1445296671,African American/Afro-Caribbean,USA
STAR135,CYP2C9*1,PHARGENE25,DRUG1,*1/*8 + *8/*8,CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.,REF74,< 0.01,PharmGKB,1444695840,African American/Afro-Caribbean,USA
STAR136,CYP2C9*8,PHARGENE25,DRUG1,*1/*8 + *8/*8,CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.,REF74,< 0.01,PharmGKB,1444695840,African American/Afro-Caribbean,USA
STAR158,CYP2C9*1,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR159,CYP2C9*11,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR160,CYP2C9*2,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR161,CYP2C9*3,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR162,CYP2C9*5,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR163,CYP2C9*6,PHARGENE25,DRUG1,*2 + *3 + *5 + *6 + *11,CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF7,0.12,PharmGKB,1447519652,African American/Afro-Caribbean,USA
STAR164,CYP2C9*1,PHARGENE25,DRUG1,*2 + *3,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF44,ambiguous,PharmGKB,1447520623,African American/Afro-Caribbean,USA
STAR165,CYP2C9*2,PHARGENE25,DRUG1,*2 + *3,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF44,ambiguous,PharmGKB,1447520623,African American/Afro-Caribbean,USA
STAR166,CYP2C9*3,PHARGENE25,DRUG1,*2 + *3,CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF44,ambiguous,PharmGKB,1447520623,African American/Afro-Caribbean,USA
STAR183,CYP2C9*1,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR184,CYP2C9*11,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR185,CYP2C9*2,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR186,CYP2C9*3,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR187,CYP2C9*5,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR188,CYP2C9*8,PHARGENE25,DRUG1,*2 + *3 + *5 + *8 + *11,CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.,REF149,ambiguous,PharmGKB,1448573256,African American/Afro-Caribbean,USA
STAR38,CYP2D6*1,PHARGENE26,DRUG31,*6,"CYP2D6 *6 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046925,African American/Afro-Caribbean,USA
STAR39,CYP2D6*6,PHARGENE26,DRUG31,*6,"CYP2D6 *6 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046925,African American/Afro-Caribbean,USA
STAR45,CYP2D6*1,PHARGENE26,DRUG31,*17,"CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046931,African American/Afro-Caribbean,USA
STAR46,CYP2D6*17,PHARGENE26,DRUG31,*17,"CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046931,African American/Afro-Caribbean,USA
STAR47,CYP2D6*1,PHARGENE26,DRUG31,*4,"CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046905,African American/Afro-Caribbean,USA
STAR48,CYP2D6*4,PHARGENE26,DRUG31,*4,"CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046905,African American/Afro-Caribbean,USA
STAR49,CYP2D6*1,PHARGENE26,DRUG31,*40,"CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046937,African American/Afro-Caribbean,USA
STAR50,CYP2D6*40,PHARGENE26,DRUG31,*40,"CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046937,African American/Afro-Caribbean,USA
STAR51,CYP2D6*1,PHARGENE26,DRUG31,*5,"CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046919,African American/Afro-Caribbean,USA
STAR52,CYP2D6*5,PHARGENE26,DRUG31,*5,"CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.",REF75,< 0.05,PharmGKB,982046919,African American/Afro-Caribbean,USA
STAR97,CYP2D6*1,PHARGENE26,DRUG31,*5/*17,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",REF49,ambiguous,PharmGKB,1184756913,Sub-Saharan African,Tanzania
STAR98,CYP2D6*17,PHARGENE26,DRUG31,*5/*17,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",REF49,ambiguous,PharmGKB,1184756913,Sub-Saharan African,Tanzania
STAR99,CYP2D6*5,PHARGENE26,DRUG31,*5/*17,"CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.",REF49,ambiguous,PharmGKB,1184756913,Sub-Saharan African,Tanzania
STAR108,CYP2D6*1,PHARGENE26,DRUG31,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,> 0.05,PharmGKB,1184756952,Sub-Saharan African,Tanzania
STAR109,CYP2D6*2,PHARGENE26,DRUG31,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,> 0.05,PharmGKB,1184756952,Sub-Saharan African,Tanzania
STAR110,CYP2D6*29,PHARGENE26,DRUG31,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of codeine or debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,> 0.05,PharmGKB,1184756952,Sub-Saharan African,Tanzania
STAR105,CYP2D6*1,PHARGENE26,DRUG36,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,< 0.05,PharmGKB,1184756941,Sub-Saharan African,Tanzania
STAR106,CYP2D6*2,PHARGENE26,DRUG36,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,< 0.05,PharmGKB,1184756941,Sub-Saharan African,Tanzania
STAR107,CYP2D6*29,PHARGENE26,DRUG36,*29/*29,CYP2D6 *29/*29 is associated with decreased metabolism of dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.,REF49,< 0.05,PharmGKB,1184756941,Sub-Saharan African,Tanzania
STAR178,CYP2D6*17,PHARGENE26,DRUG31,*17,"CYP2D6 *17 is associated with decreased metabolism of codeine in people with Anemia, Sickle Cell.",REF18,< 0.05,PharmGKB,1447963867,African American/Afro-Caribbean,USA
STAR75,CYP2D6*1,PHARGENE26,DRUG36,*17,CYP2D6 *17 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.,REF65,< 0.001,PharmGKB,1184757110,African American/Afro-Caribbean,USA
STAR76,CYP2D6*17,PHARGENE26,DRUG36,*17,CYP2D6 *17 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.,REF65,< 0.001,PharmGKB,1184757110,African American/Afro-Caribbean,USA
STAR77,CYP2D6*1,PHARGENE26,DRUG36,*29,CYP2D6 *29 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.,REF65,0.21,PharmGKB,1184757117,African American/Afro-Caribbean,USA
STAR78,CYP2D6*29,PHARGENE26,DRUG36,*29,CYP2D6 *29 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.,REF65,0.21,PharmGKB,1184757117,African American/Afro-Caribbean,USA
STAR88,CYP2D6*4,PHARGENE26,DRUG36,*6/*40 + *4/*40,CYP2D6 *6/*40 + *4/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF65,,PharmGKB,1184757079,African American/Afro-Caribbean,USA
STAR89,CYP2D6*40,PHARGENE26,DRUG36,*6/*40 + *4/*40,CYP2D6 *6/*40 + *4/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF65,,PharmGKB,1184757079,African American/Afro-Caribbean,USA
STAR90,CYP2D6*6,PHARGENE26,DRUG36,*6/*40 + *4/*40,CYP2D6 *6/*40 + *4/*40 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF65,,PharmGKB,1184757079,African American/Afro-Caribbean,USA
STAR91,CYP2D6*3,PHARGENE26,DRUG36,*3/*4xN,CYP2D6 *3/*4xN (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF65,,PharmGKB,1184986056,African American/Afro-Caribbean,USA
STAR92,CYP2D6*4xN,PHARGENE26,DRUG36,*3/*4xN,CYP2D6 *3/*4xN (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF65,,PharmGKB,1184986056,African American/Afro-Caribbean,USA
STAR83,CYP2D6*40,PHARGENE26,DRUG36,*40/*42,CYP2D6 *40/*42 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF55,,PharmGKB,1184757143,African American/Afro-Caribbean,USA
STAR84,CYP2D6*42,PHARGENE26,DRUG36,*40/*42,CYP2D6 *40/*42 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF55,,PharmGKB,1184757143,African American/Afro-Caribbean,USA
STAR93,CYP2D6*100,PHARGENE26,DRUG36,*5/*100,CYP2D6 *5/*100 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF119,,PharmGKB,1184989053,African American/Afro-Caribbean,Trinidad
STAR94,CYP2D6*5,PHARGENE26,DRUG36,*5/*100,CYP2D6 *5/*100 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF119,,PharmGKB,1184989053,African American/Afro-Caribbean,Trinidad
STAR95,CYP2D6*101,PHARGENE26,DRUG36,*2/*101,CYP2D6 *2/*101 is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF119,,PharmGKB,1184989087,African American/Afro-Caribbean,Trinidad
STAR96,CYP2D6*2,PHARGENE26,DRUG36,*2/*101,CYP2D6 *2/*101 is associated with decreased metabolism of dextromethorphan in healthy individuals.,REF119,,PharmGKB,1184989087,African American/Afro-Caribbean,Trinidad
STAR116,CYP2D6*4xN,PHARGENE26,DRUG36,*4xN/*56,CYP2D6 *4xN/*56 is associated with decreased metabolism of dextromethorphan.,REF23,,PharmGKB,1184986040,African American/Afro-Caribbean,USA
STAR117,CYP2D6*56,PHARGENE26,DRUG36,*4xN/*56,CYP2D6 *4xN/*56 is associated with decreased metabolism of dextromethorphan.,REF23,,PharmGKB,1184986040,African American/Afro-Caribbean,USA
STAR152,CYP2D6*36,PHARGENE26,DRUG36,*4/*36,CYP2D6 *4/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897132,African American/Afro-Caribbean,USA
STAR153,CYP2D6*4,PHARGENE26,DRUG36,*4/*36,CYP2D6 *4/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897132,African American/Afro-Caribbean,USA
STAR154,CYP2D6*36,PHARGENE26,DRUG36,*4xN/*36,CYP2D6 *4xN/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897141,African American/Afro-Caribbean,USA
STAR155,CYP2D6*4xN,PHARGENE26,DRUG36,*4xN/*36,CYP2D6 *4xN/*36 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897141,African American/Afro-Caribbean,USA
STAR156,CYP2D6*2,PHARGENE26,DRUG36,*2/*36,CYP2D6 *2/*36 (assigned as extensive metabolizer phenotype) is not associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897151,African American/Afro-Caribbean,USA
STAR157,CYP2D6*36,PHARGENE26,DRUG36,*2/*36,CYP2D6 *2/*36 (assigned as extensive metabolizer phenotype) is not associated with decreased metabolism of dextromethorphan.,REF76,,PharmGKB,1446897151,African American/Afro-Caribbean,USA
STAR202,CYP2D6*2,PHARGENE26,DRUG57,*2/*41,CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.,REF59,,PharmGKB,1449189944,Sub-Saharan African,Canada
STAR203,CYP2D6*41,PHARGENE26,DRUG57,*2/*41,CYP2D6 *2/*41 is associated with increased concentrations of hydrocodone.,REF59,,PharmGKB,1449189944,Sub-Saharan African,Canada
STAR129,CYP2C19*1,PHARGENE23,DRUG40,*1/*17,CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.,REF161,,PharmGKB,1444828163,Sub-Saharan African,Cameroon
STAR130,CYP2C19*17,PHARGENE23,DRUG40,*1/*17,CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole.,REF161,,PharmGKB,1444828163,Sub-Saharan African,Cameroon
